Compare BSL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | SPRO |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.3M | 156.3M |
| IPO Year | N/A | 2017 |
| Metric | BSL | SPRO |
|---|---|---|
| Price | $12.92 | $2.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $12.45 | $1.80 |
| 52 Week High | $14.35 | $3.08 |
| Indicator | BSL | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 42.65 |
| Support Level | $12.82 | $2.14 |
| Resistance Level | $12.94 | $2.52 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 40.00 | 28.64 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.